Skip to main content

Table 1 Baseline characteristics

From: Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials

Mean ± SDPREMIEROPTIMA
ADA+MTX
(n = 268)
PBO+MTX
(n = 257)
ADA+MTX
(n = 515)
PBO+MTX
(n = 517)
Age, years51.9 ± 14.052.0 ± 13.150.7 ± 14.550.4 ± 13.6
Female, n (%)193 (72.0)190 (73.9)380 (73.8)382 (73.9)
Caucasian, n (%)250 (93.3)242 (94.2)460 (89.3)464 (89.7)
Duration of RA, years0.7 ± 0.80.8 ± 0.90.3 ± 0.30.4 ± 0.6
CRP, mg/dL3.9 ± 4.24.0 ± 4.02.7 ± 3.23.0 ± 3.3
DAS28(CRP)6.3 ± 0.96.3 ± 0.96.0 ± 1.06.0 ± 1.0
CDAI43.6 ± 12.644.4 ± 11.941.3 ± 13.240.3 ± 13.3
SDAI47.4 ± 14.248.4 ± 13.444.0 ± 14.243.2 ± 14.6
TJC6830.7 ± 14.232.3 ± 14.329.0 ± 15.027.2 ± 14.5
SJC6621.1 ± 11.222.1 ± 11.718.3 ± 10.517.9 ± 10.5
PGA65.1 ± 17.665.6 ± 17.763.0 ± 17.862.2 ± 18.3
PtGA66.8 ± 22.163.0 ± 25.064.0 ± 23.062.5 ± 22.1
Pt pain62.5 ± 21.359.6 ± 24.365.0 ± 21.364.7 ± 21.2
HAQ-DI1.5 ± 0.61.5 ± 0.61.6 ± 0.71.6 ± 0.7
 DE019ARMADA
 ADA+MTX
(n = 207)
PBO+MTX
(n = 200)
ADA+MTX
(n = 67)
PBO+MTX
(n = 62)
Age, years56.1 ± 13.556.1 ± 12.057.2 ± 11.456.0 ± 10.8
Female, n (%)158 (76.3)146 (73.0)50 (74.5)51 (82.3)
Caucasian, n (%)173 (83.6)166 (83.0)58 (86.6)45 (72.6)
Duration of RA, years11.0 ± 9.210.9 ± 8.812.2 ± 11.111.1 ± 8.0
CRP, mg/dL1.8 ± 2.31.8 ± 2.12.1 ± 1.83.1 ± 3.9
DAS28(CRP)5.7 ± 0.95.8 ± 0.95.1 ± 0.75.1 ± 1.0
CDAI38.6 ± 12.240.3 ± 12.337.3 ± 10.737.3 ± 11.7
SDAI40.6 ± 13.042.1 ± 12.939.5 ± 10.740.4 ± 13.5
TJC6827.3 ± 12.728.1 ± 13.828.0 ± 12.728.7 ± 15.2
SJC6619.3 ± 9.819.0 ± 9.517.3 ± 8.616.9 ± 9.5
PGA62.0 ± 16.761.3 ± 17.358.7 ± 15.858.9 ± 15.3
PtGA52.7 ± 21.054.3 ± 22.956.9 ± 21.158.0 ± 23.2
Pt pain55.9 ± 20.456.3 ± 22.953.0 ± 22.057.2 ± 21.0
HAQ-DI1.5 ± 0.61.5 ± 0.61.6 ± 0.61.6 ± 0.6
  1. ADA adalimumab, CDAI Clinical Disease Activity index, CRP C-reactive protein, DAS28 Disease Activity Score based on 28-joints, HAQ-DI Health Assessment Questionnaire Disability Index, PBO placebo, PGA Physician Global Assessment, Pt patient, PtGA Patient Global Assessment, RA rheumatoid arthritis, SDAI Simplified Disease Activity index, SJC66 swollen joint count based on 66 joints, TJC68 tender joint count based on 68 joints